Targeted drugs for metastatic melanoma with a BRAF mutation
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 1 trial tests a combination of targeted cancer medicines to treat melanoma that has spread or cannot be removed by surgery. It is for people whose tumor has a specific BRAF mutation, and who have either stayed stable on a prior targeted treatment or no longer respond to it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have melanoma confirmed by biopsy/pathology that has spread (metastatic) or can’t be removed by surgery.
- Your tumor has a BRAF V600 mutation based on approved genetic testing.
- You must have either been stable for at least 3 months on a prior targeted treatment (dabrafenib+trametinib or encorafenib+binimetinib) or have stopped/failed one of those treatments.
- You must be 18 or older, and able to perform daily activities at a level the study calls ECOG 0–1.
- Your blood counts and key organ function (liver, kidneys, etc.) must meet minimum lab limits.
- You must have measurable disease on scans, and be willing/able to sign informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests two targeted medicines (binimetinib and encorafenib) for melanoma that has spread to the brain. It focuses on people whose tumor has a specific BRAF V600 mutation and who have brain metastases that are progressing or need treatment.
This Phase 2 study tests whether a 3-drug plan (encorafenib + binimetinib + nivolumab) works better than ipilimumab + nivolumab for melanoma that has spread to the brain. If you qualify, you’ll get either treatment and have frequent brain scans to track how well it controls the tumors.
This trial tests a combination of two or three drugs (defactinib, avutometinib, with or without encorafenib) to shrink brain tumors that started from skin melanoma. It may be an option for people whose melanoma has a specific genetic change and who have already tried immunotherapy.
This early-phase study looks at whether people with melanoma can get the “right” follow-up (extra) treatment based on how well their cancer responds after starting targeted drugs before surgery. The goal is to improve outcomes while better matching treatment to each person’s tumor response.
This study tests whether adding metformin to vemurafenib can shrink advanced melanoma in people with a specific gene change (BRAF V600E). It’s an early-phase trial, so the main goal is to see if the combination is safe and whether it may work better than expected.
This trial tests a personalized approach where doctors monitor tumor DNA in your blood to decide when to pause targeted therapy (encorafenib and binimetinib) for advanced melanoma with a BRAF mutation. The goal is to see if treatment breaks can be safe and effective.
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.